The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: Identification of a new immunotherapeutic synapse

Leukemia

Volumn 29, Issue 9, 2015, Pages 1952-1954

  Coles, S J ^a,b   Gilmour, M N ^b   Reid, R ^b   Knapper, S ^b   Burnett, A K ^b   Man, S ^b   Tonks, A ^b   Darley, R L ^b  

^a UNIVERSITY OF WORCESTER   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD200 ANTIGEN; CD200 RECEPTOR; MESSENGER RNA; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; SAMALIZUMAB; ANTIGENS, CD200; LEUKOCYTE ANTIGEN;

ACUTE MYELOBLASTIC LEUKEMIA; BLAST CELL; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LEUKEMIA CELL; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY; UPREGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PATHOLOGY;

ANTIGENS, CD; ANTIGENS, CD274; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; T-LYMPHOCYTES;

EID: 84940796130     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.62     Document Type: Letter

References (18)

1. Shah A, TM-L Andersson, Rachet B, Björkholm M, Lambert PC. Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study. Br J Haematol 2013; 162: 509-516.
2. Coles SJ, Hills RK, Wang ECY, Burnett AK, Man S, Darley RL et al. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells. Leukemia 2012; 26: 2146-2148.
3. Coles SJ, Wang ECY, Man S, Hills RK, Burnett AK, Tonks A et al. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 2011; 25: 792-799.
4. Coles SJ, Hills RK, Wang ECY, Burnett AK, Man S, Darley RL et al. Expression of CD200 on AML blasts directly suppresses memory T-cell function. Leukemia 2012; 26: 2148-2151.
5. Norde WJ, Hobo W, van der Voort R, Dolstra H. Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood 2012; 120: 728-736.
6. Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM, Soefje SA. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract 2014; doi:10.1177/1078155214538087.
7. Berthon C, Driss V, Liu J, Kuranda K, Leleu X, Jouy N et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol Immunother 2010; 59: 1839-1849.
8. Ahmad SM, Svane IM, Andersen MH. The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity. Blood Cancer J 2014; 4: e230.
9. Schalper KA. PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer. Oncoimmunology 2014; 3: e29288.
10. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002; 100: 2132-2137.
11. Beatty GL, Smith JS, Reshef R, Patel KP, Colligon TA, Vance BA et al. Functional unresponsiveness and replicative senescence of myeloid leukemia antigenspecific CD8+ T cells after allogeneic stem cell transplantation. Clin Cancer Res 2009; 15: 4944-4953.
12. Santegoets SJAM, Turksma AW, Suhoski MM, Stam AGM, Albelda SM, Hooijberg E et al. IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. J Transl Med 2013; 11: 37.
13. Youde SJ, McCarthy CM, Thomas KJ, Smith KL, Man S. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line. Int J Cancer 2005; 114: 606-612.
14. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011; 117: 4501-4510.
15. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013; 73: 3591-3603.
16. Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007; 21: 566-568.
17. Sun W-J, Li X. B7-H1, a prognostic factor for patient's response to therapy of acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2012; 20: 1332-1335.
18. Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ, Bowdish KS. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol 2008; 180: 699-705.